Page 424 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 424

Appendix Table C3.2. KQ3 multivariable analyses (continued)
                                            Author          Factors       Data source      Duration      Analyzed         Population         WW/AS          Methods          Results as described in paper
                                              yr                                                          sample        characteristics  definitions
                                             PMI

                                                                                                                                                                           Model stratified by number of
                                                                                                                                                                           comorbidities:
                                                                                                                                                                           no comorbidities, using WW as the
                                                                                                                                                                           baseline,
                                                                                                                                                                             - BT: ≥75 yr vs. <75 yr,
                                                                                                                                                                           OR=0.165 (CI 0.068, 0.400)
                                                                                                                                                                             - BT + EBRT: ≥75 yr vs. <75 yr,
                                                                                                                                                                           OR=0.139 (CI 0.038, 0.516)
                                                                                                                                                                             - EBRT: ≥75 yr vs. <75 yr,
                                                                                                                                                                           OR=0.400 (CI 0.178, 0.898)
                                                                                                                                                                             - PADT: ≥75 yr vs. <75 yr,
                                                                                                                                                                           OR=0.385 (CI 0.171, 0.866)
                                                                                                                                                                             - RP: ≥75 yr vs. <75 yr, OR=
                                                                                                                                                                           0.004 (CI 0.001, 0.015)

                                                                                                                                                                           See paper for other comorbidity
                                                                                                                                                                           categories
                                                                                                                                                                           Results were adjusted for
                                                                                                                                                                           demographic and risk covariates,
                                                                                                                                                                           and accruing site.


































                                                                                                                        C-130
   419   420   421   422   423   424   425   426   427   428   429